JB Pharma Q3 Results: Net profit rises 26% to Rs 106 crore
The earnings before interest, tax, depreciation and ammortisation (EBITDA) rose 28% YoY to Rs 193 crore. The EBTIDA margin dropped 120 basis points YoY to 24.3%.The domestic formulation sales that contribute over half of company’s sales recorded a growth of 42% YoY to Rs 407 crore, while the international formulation rose 23% to Rs 386 crore
